Ablynx

@AblynxABLX

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies® for a range of serious human diseases.

Ghent/Zwijnaarde, Belgium
ablynx.com
Registrerte seg mai 2012
5 bilder og videoer Bilder og videoer

Tweets

Du har blokkert @AblynxABLX

Er du sikker på at du vil vise disse tweetene? Dette vil ikke oppheve blokkeringen av @@AblynxABLX.

  1. Retweetet
    26. jul.

    FDA designates top nanobody caplacizumab fast track designation: 6-10 months faster approval

    3 retweets 4 liker
  2. Retweetet
    20. jul.

    2.4bn "bioeuro": Belgian Nanobody delights now also tasteful in France

    2 retweets 7 liker
  3. 20. jul.

    and Sanofi to develop up to 8 Nanobody®-based therapeutics focused on immuno-inflammatory diseases

    1 svar 9 retweets 14 liker
  4. 27. jun.

    achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc.

    7 retweets 16 liker
  5. 26. jun.

    initiates a single and multiple dose Phase I study of caplacizumab in healthy Japanese subjects

    4 retweets 6 liker
  6. 29. mai

    launches , a new website dedicated to Thrombotic Thrombocytopenic Purpura (TTP)

    10 retweets 9 liker
  7. 22. mai

    receives €15M milestone from Merck KGaA for novel Nanobody in osteoarthritis

    10 retweets 12 liker
  8. 18. mai

    Meet our experts and recruiters (booth 99) @

    2 liker
  9. 11. mai

    Ablynx zit op schema via

    4 retweets 6 liker
  10. 11. mai

    Q1 2017 "Positive start of the year; good progress in multiple programmes; strong cash position"

    6 retweets 4 liker
  11. 10. mai

    Publication in Journal of Thrombosis and Haemostasis "Caplacizumab reduces major thromboembolic events"

    7 retweets 7 liker
  12. 2. mai

    successfully completes patient recruitment in its Phase III Hercules study of caplacizumab

    2 retweets 6 liker
  13. 7. apr.

    Annual Report 2016 is available online - view via

    1 retweet 4 liker
  14. 7. apr.

    - Adrianus van Herk (aandeelhouder Ablynx): 'België en Nederland zijn wereldtop' via @trends

    1 retweet 4 liker
  15. Retweetet
    6. mar.

    Compelling data for developed psoriasis nanobody in collaboration

    3 retweets 2 liker
  16. Retweetet
    28. feb.

    Good morning to those waking up in Europe, Africa and the Middle East! Share with us what you have planned for today!

    15 svar 51 retweets 103 liker
  17. Retweetet
    24. feb.

    you will find out that is dedicated to creating new medicines which will make a real difference to society!

    1 retweet 1 liker
  18. 23. feb.

    FYR 2016: significant progress in R&D pipeline; strong cash position; major catalysts in 2017.

    4 retweets 3 liker
  19. 9. feb.

    will present additional data from the Phase IIb RA combination study of vobarilizumab at the Annual CRA Meeting

    2 retweets 2 liker
  20. 6. feb.

    Ablynx files caplacizumab for ultra rare blood disorder
    6 retweets 9 liker

@AblynxABLX har ikke Tweetet enda.

Lastingen ser ut til å ta sin tid.

Twitter kan være overbelastet, eller det kan ha oppstått et midlertidig problem. Prøv igjen, eller se Twitters status for mer informasjon.

    Du vil kanskje også like

    ·